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Significance {#sec1}
============

**Tasmanian devils are threatened with extinction by a horizontally transmitted cancer termed devil facial tumor disease (DFTD). Using an integrative systems-wide approach, this study identifies the ERBB-STAT3 signaling axis as a central molecular driver of DFTD. Pharmacological targeting of this axis in cell culture and in xenograft mouse models inhibited tumor growth and restored the expression of MHC class I genes. These results extend our understanding of the molecular signaling cascades driving DFTD and provide a potential explanation why horizontally transmitted DFTD cells are not rejected by the immune system. Pharmacological interference with ERBB-STAT3 may provide a much-needed addition to the ongoing efforts to save Tasmanian devils from transmissible cancer.**

Introduction {#sec2}
============

Cancer cells do not usually transmit between individuals. No human examples of transmissible cancers are known apart from rare iatrogenic cases during surgery and transplantation or materno-fetal transmission ([@bib36], [@bib51], [@bib53]). Accordingly, horizontal transmission is not considered a hallmark of cancer ([@bib29]). Yet, at least six species in the animal kingdom harbor clonal cancers which spread horizontally within populations ([@bib55], [@bib65]). These diseases include the fatal devil facial tumor disease (DFTD) in Tasmanian devils ([@bib58], [@bib57], [@bib66], [@bib79]), a sexually transmitted sarcoma in dogs ([@bib24], [@bib59], [@bib60]), and leukemia-like cancers in mollusks ([@bib54], [@bib55]). Genetic studies provided invaluable insights into these unusual cancers but the molecular underpinnings of malignancy and transmissibility remain poorly understood.

DFTD is an allogeneic graft of Schwann cell origin, which is transmitted by direct transfer of living cancer cells from one individual to another as a result of biting behavior during feeding or mating interactions ([@bib58], [@bib66]). Diseased devils succumb to the disease within months ([@bib47]), rendering DFTD a serious threat to the survival of the population of the largest living marsupial carnivore. Several mechanisms are thought to confer the tumor cells with the property of being successfully transmitted between individual Tasmanian devils, including the lack of rejection due to the low expression levels of major histocompatibility complex (MHC) class I genes and diminished genetic diversity ([@bib76], [@bib77]). Despite recent efforts, vaccines and treatments showed limited success against DFTD ([@bib43], [@bib85]). A second transmissible cancer was discovered in 2014 ([@bib69]), which has been termed DFT2 to distinguish it from the first transmissible DFTD, now termed DFT1. In this study DFTD refers to DFT1, first identified in 1996 ([@bib66]).

In this study we investigate DFTD-specific aberrant signaling pathways in order to understand and exploit the underlying molecular wiring of this transmissible cancer for potential therapeutic avenues.

Results {#sec3}
=======

ERBB-Specific Vulnerability of DFTD Identified by Pharmacological Screening {#sec3.1}
---------------------------------------------------------------------------

To address the inherent limitations of working with non-model organisms such as the Tasmanian devil, we characterized cell lines and primary biopsies ([Table S1](#mmc2){ref-type="supplementary-material"}) through an integrative and unbiased systems-biology approach consisting of pharmacological screens, transcriptomics, proteomics, and epigenomics. First, we performed a cell viability screen with over 2,500 selected compounds against 4 DFTD tumor cell lines (T1--T4) on an automated high-throughput screening platform to identify potential pharmacological vulnerabilities ([Table S2](#mmc3){ref-type="supplementary-material"}). A fibroblast cell line of Tasmanian devil origin served as control ([@bib57]). Sixty-nine compounds killed at least one out of four DFTD tumor cell lines, but did not affect the viability of fibroblasts, as measured by intracellular ATP levels ([Figure 1](#fig1){ref-type="fig"}A; [Table S2](#mmc3){ref-type="supplementary-material"}). Interestingly, this unbiased approach yielded a substantial enrichment of tyrosine kinase inhibitors targeting selectively the ERBB receptors (29/69; 42%) including lapatinib, erlotinib, and sapitinib ([Figure 1](#fig1){ref-type="fig"}B, [Table S2](#mmc1){ref-type="supplementary-material"}). In addition, we observed DFTD tumor cell-specific killing for inhibitors for histone deacetylases (HDAC), BET bromodomains and other potential therapeutic targets ([Figure 1](#fig1){ref-type="fig"}A, [Table S2](#mmc1){ref-type="supplementary-material"}). The human ERBB family has four members (*EGFR*, *ERBB2*, *ERBB3*, and *ERBB4*) ([@bib34]), of which the devil genome has all orthologs annotated except *ERBB4*. Interestingly, DFTD cells expressed higher transcript levels of *ERBB2* and *ERBB3* compared with fibroblasts, while *EGFR* was barely detectable ([Figure 1](#fig1){ref-type="fig"}C). To validate this finding on the protein level, we tested antibodies with cross-species recognition ([Table S1](#mmc2){ref-type="supplementary-material"}). Western blot analysis confirmed increased levels of total ERBB2 and ERBB3 in DFTD cell lines compared with fibroblasts ([Figure 1](#fig1){ref-type="fig"}D). The phosphorylated residues Y1221/1222 (ERBB2) and Y1289 (ERRB3) are conserved across species ([Table S1](#mmc2){ref-type="supplementary-material"}), highlighting the evolutionary impact of tyrosine kinase signaling in cancer cells. Likewise, sequence alignments with \>95% conserved amino acids in its protein kinase domain suggest that Tasmanian devil ERBB3 is a pseudokinase as known from other vertebrates. Phospho-site-specific antibodies provided evidence for persistent activation of ERBB2 and ERBB3 ([Figure 1](#fig1){ref-type="fig"}D). These results were corroborated by immunohistochemical detection of increased expression of ERBB2 and ERBB3 in primary tumor biopsies of diseased Tasmanian devils compared with adjacent non-tumor tissue ([Figures 1](#fig1){ref-type="fig"}E and 1F). Tumor cells were identified by the DFTD diagnostic marker Periaxin (PRX) ([@bib58], [@bib84]). To control for the Schwann cell origin of DFTD, we also analyzed PRX-positive peripheral nerve tissue and found that DFTD tumors express elevated levels of ERBB2 and ERBB3 compared with nerve tissue ([Figures 1](#fig1){ref-type="fig"}E and F). Transcriptional profiling of DFTD tumor cell lines T1-T4 and fibroblasts revealed differentially expressed transcripts and predicted transcription factors driving this differential gene regulation ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D; [Table S3](#mmc4){ref-type="supplementary-material"}). Among the predicted upregulated pathways was ERBB family signaling ([Figure 1](#fig1){ref-type="fig"}G). The genes driving this enrichment included *HBEGF*, *EGF*, and *NRG1* that encode ERBB ligands, *ERBIN* and *CPNE3* that encode positive regulators, and the proto-oncogene *FOS* (all increased expression), as well as *EREG* and *PTPN12* (decreased expression) that encode negative regulators ([Figure 1](#fig1){ref-type="fig"}G). We corroborated the differential expression of the ERBB ligands in primary DFTD tumor tissue by real-time PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Due to its marked upregulation, we also included *EGFL8*, which encodes the putative ERBB ligand epithelial growth factor-like domain multiple 8, in our analysis ([Figures 1](#fig1){ref-type="fig"}H, [S1](#mmc1){ref-type="supplementary-material"}E, and S1F). Of note, variant analysis of our high-coverage RNA sequencing (RNA-seq) data did not provide any evidence for activating mutations in expressed devil orthologous genes of the involved pathways ([Figures S1](#mmc1){ref-type="supplementary-material"}G--S1I; [Table S4](#mmc){ref-type="supplementary-material"}). Together, these data indicate that DFTD tumor cells, which express high levels of phosphorylated ERBB2 and ERBB3 and show activation of the ERBB signaling pathway, are exquisitely vulnerable to ERBB kinase inhibitors.Figure 1A Pharmacological Screen Identified ERBB-Specific Vulnerability of DFTD(A) The targets of the 69 drug hits in the 4-point drug screen showing a reduction in cell viability in at least 1 of the 4 DFTD cell lines compared with healthy fibroblasts.(B) Eight-point dose-response curves for lapatinib, erlotinib, and sapitinib in four tumor cell lines (T1--T4) and fibroblasts (Fib.) shown as normalized percentage of control (POC).(C) Expression of the ERBB family members quantified by real-time PCR (n = 3 replicates).(D) Western blots of the three annotated ERBB proteins (total and phosphorylated).(E) Histopathological analysis of tumor and peripheral nerve biopsies for H&E and immunohistochemistry (IHC) against Periaxin (PRX), ERBB2, and ERBB3 on serial consecutive sections. Dotted rectangles indicate magnified areas. Scale bars, 200 and 25 μm.(F) Quantification of ERBB2 and ERBB3 signal in tumor biopsies, adjacent tissue, and peripheral nerve tissue. Statistical significance was calculated by unpaired t test.(G) MetaCore pathway maps enrichments separately for up- (red) and downregulated (blue) transcripts in tumor cell lines versus fibroblasts. Only the first ten pathways and with a false discovery rate ≤0.05 are reported.(H) Heatmap of RNA-seq expression for genes driving the MetaCore pathway "ERBB-family signaling" (bold gene symbols) as well as known positive (*ERBIN* and *CPNE3*) and negative (*EREG* and *PTPN12*) regulators of the ERBB pathway and *EGFL8* in four DFTD cell lines (T1--T4) and fibroblasts (Fib.).Graphs represent the mean ± SEM. See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, and [S4](#mmc){ref-type="supplementary-material"}.

Characterization of DFTD by Integrated Proteomic and DNA Methylation Analysis {#sec3.2}
-----------------------------------------------------------------------------

To unravel the involved signaling cascades in DFTD, we investigated global changes in protein abundance in primary biopsies of diseased devils by proteomic analysis. This approach included DFTD tumor tissue as well as healthy control tissue from skin and spleen from four Tasmanian devils from different geographical locations as well as peripheral nerve tissue and the DFTD tumor cell line T1 ([Table S1](#mmc2){ref-type="supplementary-material"}). Overall, we identified 6,672 unique proteins across all samples searched against a Uniprot reference library of the devil ([Figure S2](#mmc1){ref-type="supplementary-material"}A, [Table S5](#mmc6){ref-type="supplementary-material"}). A total of 4,981 of these identified proteins were detected across more than 80% of the samples ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). This unbiased expression proteomic approach was not specifically designed to enrich for hydrophobic transmembrane proteins such as ERBB2 and ERBB3. Principal-component analysis of the 3,894 proteins quantified in all samples distinguished the replicates according to the tissue of origin, with the first principal component accounting for 41.1% of the inter-sample variability differentiating tumor from healthy samples ([Figure 2](#fig2){ref-type="fig"}A). Upon differential analysis of tumor versus healthy tissues we defined a tumor-modulated signature of 987 proteins ([Figure 2](#fig2){ref-type="fig"}B; [Table S5](#mmc6){ref-type="supplementary-material"}). Among the most prominent proteins overexpressed in tumor tissue we identified the oncogenic transcription factor STAT3 ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}D). Downstream targets of STAT3, among which matrix metalloproteinase 2 (MMP2) ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}E--S2G) ([@bib93]) is also differentially modulated in the tumor biopsies. We detected MMP2, which is secreted as a proprotein, at high abundance in tumor biopsies but not in the DFTD cell line. This may be due to technical limitations or could indicate its extracellular secretion in the tumor microenvironment. Tumor tissue also expressed high levels of the histone deacetylase HDAC5 and the SUMO/ubiquitin E3 ligase TRIM28, which is linked to STAT3 signaling ([@bib86]), as well as low expression of the tumor suppressor PTGIS ([Figure 2](#fig2){ref-type="fig"}C). Further, our proteomic analysis confirmed the high expression levels of the EGFL8 in DFTD tumor cells ([Figures 2](#fig2){ref-type="fig"}C, [1](#fig1){ref-type="fig"}H, and [S1](#mmc1){ref-type="supplementary-material"}F). Pathway enrichment analysis highlighted downregulation of processes related to chemotaxis, cell adhesion, and cytoskeleton remodeling ([Figures S2](#mmc1){ref-type="supplementary-material"}H and S2I; [Table S5](#mmc6){ref-type="supplementary-material"}), some of which are negatively regulated by STAT3 ([@bib42], [@bib95]).Figure 2Integrative Systems-Level Analysis of DFTD(A) Principal-component analysis of the 3,894 proteins quantified in all samples. Sampling locations are indicated in capital letters. Cell line denotes the DFTD cell line 06/2887 (T1) and "Nerve" stands for a healthy nerve biopsy.(B) Hierarchical clustering of the 987 differentially modulated proteins between tumor and healthy biopsies.(C) Boxplots of selected protein abundance across conditions in DFTD cell line (T1) and biopsies of tumor (T), spleen (Sp), skin (Sk), and nerve tissue (N).(D) Volcano plot of genes with differentially methylated promoters between healthy and tumor biopsies (hypermethylated in tumor \[blue\], hypomethylated in tumor \[red\]).(E) Boxplot of differentially methylated gene promoters for selected genes.(F) Direct connection proteins network among the 987 tumor-modulated proteins, 166 tumor differentially methylated gene promoters, and *ERBB2* and *ERBB3* from the drug screen and RNA-seq. The direct network interactions were built with MetaCore based on protein-protein binding, transcriptional regulation, and phosphorylation interactions. Tumor signature proteins do not have a border, while methylation candidates are represented with a black border. The ERBB2 candidate from the drug screen has a dashed black border. Of the 632 entities showing direct connectivity, only nodes with ten or more connections in MetaCore are displayed. The area of each entity is proportional to the number of connections within the network. Modulation on tumor versus healthy proteomics differential analysis, or healthy versus tumor for methylation, is colored from blue (down-modulated) to red (up-modulated).Boxplot boundaries mark the first and third quartiles, whiskers extending to 1.5 interquartile range from the boundaries, with the median in the center. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"} and [Tables S5](#mmc6){ref-type="supplementary-material"} and [S6](#mmc7){ref-type="supplementary-material"}.

In complementation to the proteomic characterization we mapped DNA methylation by reduced representation bisulfite sequencing to depict the landscape of epigenetic regulation in the aforementioned primary biopsies from Tasmanian devils. Quantification of CpG methylation was performed by an unbiased *de novo* approach ([@bib41]). For the subsequent analysis, due to the imperfect genome annotation of this non-model organism, we focused on the identification of methylated CpGs in promoter regions. DNA methylation marks readily distinguished tumor and healthy tissue and identified tumor-specific methylation signatures and their putative transcription factor binding sites ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3J). Differential analysis of tumor versus healthy biopsies highlighted 166 candidate genes with different DNA methylation levels in their promoters ([Figures 2](#fig2){ref-type="fig"}D and 2E; [Table S6](#mmc7){ref-type="supplementary-material"}), which included the tumor-specific hypomethylated *EGFL8* promoter as well as hypermethylated promoters of *ESR1*, *PTGIS*, and *GATA3* ([Figure 2](#fig2){ref-type="fig"}E). Comparative analysis by gene set enrichment revealed a high concordance of RNA-seq-derived transcript levels and proteomic data in the DFTD cell line ([Figure S3](#mmc1){ref-type="supplementary-material"}K) and was in line with an inverse correlation pattern of methylated promoter regions and respective gene transcript level ([Figures S3](#mmc1){ref-type="supplementary-material"}L and S3M). An integrative network analysis of the identified drug vulnerabilities, protein and methylation signatures revealed a high connectivity in the molecular wiring of DFTD ([Figure 2](#fig2){ref-type="fig"}F; [Table S6](#mmc7){ref-type="supplementary-material"}). This suggested a critical involvement of central oncoprotein hubs consisting of STAT3, TRIM28, and others, which may be triggered by ERBB kinase action.

Molecular Dissection of ERBB-STAT3 Axis in DFTD {#sec3.3}
-----------------------------------------------

The proteomic tumor signatures revealed increased levels of STAT3, which can become activated by ERBB receptor tyrosine kinase signaling, as well as an enrichment of STAT3 target genes ([Figures 2](#fig2){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}E, and S2F; [Table S5](#mmc6){ref-type="supplementary-material"}). Due to the central roles of STAT3 in cancer and immunity ([@bib88], [@bib96]) and the remarkably conserved amino acid sequences of STAT3 between *H. sapiens* and *S. harrisii* (99.09%), we investigated the levels of expression and activation of STAT3 by western blot. STAT3 is activated by phosphorylation of residues Y705 and S727. Thus, we tested antibodies specific to these phosphorylated residues and found highly increased STAT3 phosphorylation of both residues in DFTD tumor cells compared with fibroblasts ([Figure 3](#fig3){ref-type="fig"}A, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B). Interestingly, we also found a robust upregulation of protein tyrosine phosphorylation compared with fibroblasts ([Figure 3](#fig3){ref-type="fig"}B), indicating increased tyrosine kinase signaling. ERBB family members activate RAS-RAF-MAPK/ERK, which in turn phosphorylates STAT3 at S727 ([@bib12]). Indeed, we detected increased ERK1/2 phosphorylation in DFTD tumor cells ([Figure 3](#fig3){ref-type="fig"}C). STAT3 phosphorylation was corroborated by immunohistochemical stainings in primary tumor biopsies, showing higher levels of STAT3 phosphorylation at residues S727 and Y705 compared with adjacent non-tumor tissue or peripheral nerve tissue ([Figure 3](#fig3){ref-type="fig"}D).Figure 3Molecular Dissection of ERBB-STAT3 Axis in DFTD(A) Western blots of total STAT3, pS-STAT3, and pY-STAT3 of four DFTD cell lines (T1--T4) and fibroblasts (Fib.).(B) Total protein phosphorylation immunoblots from lysates of four DFTD cell lines (T1--T4) and fibroblasts (Fib.) using a global anti-pY monoclonal antibody (4G10) in different input amounts.(C) Western blots of total ERK1/2 and pT/Y-ERK1/2 of four DFTD cell lines (T1--T4) and fibroblasts (Fib.).(D) Representative images of IHC for total STAT3, pS-STAT3, pY-STAT3, and PRX in primary tumor and peripheral nerve biopsy on serial consecutive sections and quantification of total STAT3, pS-STAT3, and pY-STAT3 in tumor biopsies, adjacent tissue, and peripheral nerve tissue. Dotted rectangles indicate magnified areas. Scale bars, 200 and 25 μm.(E) Five-point dose-response curve of cell lines to the STAT3 inhibitor PG-S3-009 with DFTD and fibroblast cell lines.(F) Structure of DR-1-55.(G) Five-point dose-response curve of cell lines to the STAT3 inhibitor DR-1-55 with DFTD and fibroblast cell lines.(H) DFTD cells treated with 2 μM PG-S3-009, 4 μM DR-1-55, or DMSO as control. Twenty-four hours after treatment, expression of *ERBB2* and *ERBB3* was measured by real-time PCR (n = 3 replicates).(I) Western blots of total STAT3, pS-STAT3, and pY-STAT3 upon treatment with the ERBB inhibitors lapatinib (1 μM) and sapitinib (1 μM).Statistical significance was calculated by (D and H) unpaired t test. Graphs represent the mean ± SEM. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Treatment with the covalent STAT3-selective inhibitor PG-S3-009 ([@bib26]) resulted in DFTD tumor cell-specific killing ([Figure 3](#fig3){ref-type="fig"}E) and reduced STAT3 phosphorylation of residue Y705 ([Figure S4](#mmc1){ref-type="supplementary-material"}C). In addition, treatment with DR-1-55, another selective STAT3 inhibitor that covalently modifies a cysteine in the SH2 domain of STAT3 via a nucleophilic attack ([Figures 3](#fig3){ref-type="fig"}F, [S4](#mmc1){ref-type="supplementary-material"}D, and S4E), reduced the expression of the STAT3 target gene *MMP2* ([Figure S4](#mmc1){ref-type="supplementary-material"}F). We observed similar effects of DFTD tumor cell-specific killing with both STAT3 inhibitors ([Figure 3](#fig3){ref-type="fig"}G). Further, pharmacological inhibition of STAT3 by either PG-S3-009 or DR-1-55 led to reduced expression of *ERBB2* and *ERBB3* ([Figure 3](#fig3){ref-type="fig"}H). In line with this, DFTD tumor cells expressed higher levels of TRIM28 compared with fibroblasts ([Figure S4](#mmc1){ref-type="supplementary-material"}G), and blockade of either ERBB signaling or STAT3 led to reduced transcription of *TRIM28* ([Figure S4](#mmc1){ref-type="supplementary-material"}H). We also found abolished expression of the suppressor of cytokine signaling 1 (SOCS1) in DFTD tumor cells ([Figures S4](#mmc1){ref-type="supplementary-material"}I and S4J), a known inhibitor of STAT3 activation ([@bib78]). Intriguingly, treatment with ERBB inhibitors lapatinib and sapitinib inhibited serine and tyrosine phosphorylation of STAT3 ([Figure 3](#fig3){ref-type="fig"}I). In summary, our results suggest that DFTD tumor cells exhibit an ERBB-dependent constitutive activation of STAT3 in a positive feedforward loop.

Hyperactivated ERBB-STAT3 Reduces Expression of MHC Class I-Related Genes {#sec3.4}
-------------------------------------------------------------------------

Transmissibility of DFTD has been linked to reduced expression of MHC class I genes ([@bib75]), which prompted us to assess a potential link between hyperactive ERBB-STAT3 and MHC class I gene expression. To this end we stimulated DFTD tumor cells with recombinant autologous interferon γ (rIFN-γ). This induced the expression of *B2M* and *SAHA-UC*, one of Tasmanian devil\'s MHC class I genes, as shown previously ([Figure 4](#fig4){ref-type="fig"}A) ([@bib75]). Treatment with the ERBB inhibitor sapitinib alone was insufficient to induce MHC class I genes, which suggested an additional signaling requirement. Importantly, concomitant treatment of rIFN-γ with sapitinib amplified increased expression of *B2M* and *SAHA-UC* ([Figures 4](#fig4){ref-type="fig"}A and 4B). In addition, we observed increased expression of *STAT1* and a trend toward reduced *STAT3* expression upon treatment with rIFN-γ and sapitinib ([Figures 4](#fig4){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). *B2M* and *SAHA-UC* are bona fide STAT1 target genes. Thus, we hypothesized that high levels of STAT3 may interfere with STAT1 transcriptional regulation. Indeed, reciprocal co-immunoprecipitation confirmed physical interaction between STAT3 and STAT1 ([Figure 4](#fig4){ref-type="fig"}B). This was corroborated by co-localization of STAT3 and STAT1 in DFTD tumor cells ([Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C).Figure 4Blockade of ERBB Induces MHC Class I Gene Expression(A) DFTD tumor cell line T1 was treated with recombinant interferon-γ (rIFN-γ) and/or 1 μM sapitinib. Control cells were treated with solvents. Forty-eight hours after treatment, expression of *B2M*, *SAHA-UC*, *STAT1*, and *STAT3* were measured by real-time PCR (n = 3 replicates).(B) Reciprocal co-immunoprecipitation of STAT3 and STAT1 followed by western blots for STAT3 and STAT1 in DFTD tumor cell line (T1), fibroblasts, and human HT29 colon cancer cells as control.(C and D) Tumor volume (C) and tumor weight (D) of DFTD tumor cell line T1 transplanted into NSG mice and treated with either vehicle or 50 mg/kg sapitinib once daily (bilateral tumors, n = 5 mice per group). One out of two representative experiments is shown.(E) H&E and IHC analyses for total STAT3, pS-STAT3, pY-STAT3, Ki67, and Cleaved Caspase 3 of tumor tissues. Pictures shown are from contiguous sections. Dotted rectangles indicate magnified areas. Quantification of total STAT3, pS-STAT3, pY-STAT3, Ki67, and Cleaved Caspase 3. Scale bars, 200 and 25 μm.(F) Western blots for total STAT3, pY-STAT3, pS-STAT3, and STAT1 from representative xenograft tumors.(G) Expression of *B2M* and *STAT3* by real-time PCR from xenograft tumor tissue.Statistical significance was calculated by (A) one-way or (C) two-way ANOVA with Bonferroni correction or (D, E, and G) unpaired t test. Graphs represent the mean ± SEM. See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

To test the effects of ERBB inhibition *in vivo*, we transplanted DFTD tumor cells (T1) subcutaneously into the flanks of NOD/SCID gamma (NSG) mice and, 21 days later when tumors were palpable, started to administer 50 mg/kg sapitinib or vehicle once daily. DFTD xenografts in the control group proliferated rapidly after transplantation, while treatment with sapitinib effectively stalled tumor growth ([Figures 4](#fig4){ref-type="fig"}C, 4D, and [S6](#mmc1){ref-type="supplementary-material"}A). No drug toxicity was observed as assessed by the serum concentration of the liver transaminases alanine aminotransferase and aspartate aminotransferase and the kidney parameter blood urea nitrogen ([Figure S6](#mmc1){ref-type="supplementary-material"}B) and by histopathology ([Figure S6](#mmc1){ref-type="supplementary-material"}C). The observed anti-tumor effect of sapitinib was corroborated by histological analysis of tumor tissue for total STAT3, pS-STAT3, and pY-STAT3, as well as by staining for Ki67 and Cleaved Caspase 3 ([Figure 4](#fig4){ref-type="fig"}E). DFTD xenograft tumors from mice treated with sapitinib showed reduced STAT3 serine and tyrosine phosphorylation and increased expression of *B2M* ([Figures 4](#fig4){ref-type="fig"}F and 4G). Moreover, we also assessed the therapeutic effects of STAT3 inhibition by treating NSG mice 22 days after DFTD cell transplantation with 10 mg/kg DR-1-55 each second day. Similar to sapitinib, DR-1-55 resulted in reduced tumor growth ([Figures 5](#fig5){ref-type="fig"}A and 5B) without observed toxicity ([Figures 5](#fig5){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}D). Treatment with DR-1-55 resulted in pronounced reduction of pY STAT3 ([Figures 5](#fig5){ref-type="fig"}D and 5E) and reduced MMP2 expression ([Figure 5](#fig5){ref-type="fig"}D). Further, DR-1-55 increased the expression of *B2M*, while *STAT3* expression was decreased ([Figure 5](#fig5){ref-type="fig"}F). In contrast to our results *in vitro* ([Figure 4](#fig4){ref-type="fig"}A), we noted that treatment of xenografted mice with sapitinib or DR-1-55 alone was sufficient to increase *B2M* ([Figures 4](#fig4){ref-type="fig"}G and [5](#fig5){ref-type="fig"}F), possibly indicating additional host-derived signals *in vivo*. Taken together, our results derived from cell culture and xenograft models provide strong evidence for a central role of the ERBB-STAT3 axis in growth and immune evasion of DFTD.Figure 5Xenograft Model with STAT3 Inhibitor DR-1-55(A and B) Tumor volume (A) and tumor weight (B) of NSG mice transplanted with DFTD tumor cell line T1 and, 22 days after transplantation, treated with either vehicle or 10 mg/kg DR-1-55 each day (bilateral tumors, n = 5 mice per group).(C) Serum concentration of alanine aminotransferase, aspartate aminotransferase, and blood urea nitrogen.(D) Tumor tissue immunohistochemically stained and quantified for total STAT3, pS-STAT3, pY-STAT3, Ki67, Cleaved Caspase 3, and MMP2. Pictures shown are from contiguous sections. Dotted rectangles indicate magnified areas. Scale bars, 200 and 25 μm.(E) Western blots for total STAT3, pY-STAT3, pS-STAT3, and STAT1 from representative xenograft tumors.(F) Expression of *B2M* and *STAT3* by real-time PCR from xenograft tumor tissue.Statistical significance was calculated by (A) two-way ANOVA with Bonferroni correction or (B--D and F) unpaired t test. Graphs represent the mean ± SEM. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec4}
==========

ERBB signaling is influenced by ligand-induced activation and triggers downstream processes, such as context-dependent activation of transcriptional regulators, including members of the activator protein-1 family (AP-1, also bona fide STAT3 targets), ETS, and STAT3/5 transcription factors ([@bib44], [@bib73]). ERBB family genes are frequently overexpressed, amplified or mutated in human solid cancers and ERBB family members are targets of clinical therapies ([@bib2], [@bib5], [@bib71], [@bib94]). In Schwann cells, ERBB2/3 signaling regulates expansion and migration of progenitor cells as well as different functions in myelination and repair of axons ([@bib16], [@bib61], [@bib81]). Moreover, we found increased expression of proteins associated with epithelial to mesenchymal transition (EMT) process in DFTD tumors that are also upregulated in Schwann cells upon nerve injury to support axon regeneration ([@bib11], [@bib23], [@bib90]). This included the EMT-inducing zinc-finger E-box-binding homeobox factor (ZEB2) ([@bib15]) and the STAT3 target MMP2, which enhances the degradation of extracellular matrix proteins and cancer cell invasion ([@bib62]). The regenerative properties of Schwann cells are highly linked to their plasticity whereby, upon nerve injury, they reversibly de-differentiate, acquire high motility, and guide the growth of the damaged axons ([@bib40]). Thus, the identification of hyperactivated ERBB-STAT3 signaling in DFTD may suggest aberrant regulation of the Schwann cell-intrinsic repair program ([@bib3]). Of note, DFT2 tumors are pathologically similar but stain-negative for the Schwann cell marker PRX ([@bib69]) and display copy-number gains for PDGFR ([@bib79]). It will be interesting to investigate the involvement of similar driver tyrosine kinase-STAT3 pathways blocking MHC class I.

A major enigmatic question of DFTD concerns the molecular properties that are required for transmission between individuals to explain the lack of rejection. Changes in MHC class I expression and diversity have been described in transmissible tumors of devils and dogs ([@bib6]). Of note, recent immunotherapy trials with MHC-induced DFTD cells showed immunogenicity *in vivo* ([@bib85]). Our data indicate that targeting of the hyperactivated ERBB-STAT3 axis re-establishes the expression of MHC class I, thus facilitating MHC-mediated tumor immunosurveillance in Tasmanian devils ([Figure 6](#fig6){ref-type="fig"}). Promoters of interferon-stimulated MHC class I-related genes are targets for STAT1, while STAT3 is known to interfere with transcription by sequestering STAT1 in the cytoplasm through heterodimerization ([@bib25], [@bib63], [@bib80]). We hypothesize that the endogenous tonic interferon-STAT-MHC class I axis in DFTD is disrupted due to high STAT3 action promoting cancer cell proliferation, survival, and invasion. Interestingly, STAT3 overexpression was previously proposed as one of several candidate mechanisms of immune evasion in transplantation and transmissible tumors ([@bib22]). Next to the potential interference of STAT3 with expression of MHC-I, there may also be a role for TRIM28, which we found to be overexpressed in DFTD and which acts as a negative regulator of interferon signaling ([@bib45]). Of note, reduced expression of MHC-I is expected to impair rejection by CD8^+^ T cells only but not by natural killer cells, which recognize cells in the absence of MHC-I. Natural killer cells of Tasmanian devils, however, lack the ability to directly recognize DFTD cells ([@bib9], [@bib10], [@bib67]), which is likely to contribute to the lack of rejection of horizontally transmitted tumor cells. Together, our findings may bear relevance also for other transmissible cancers in higher organisms including dogs, whose transmissible tumor lacks B2M and shows low MHC class I surface expression ([@bib14], [@bib60]).Figure 6Working Model for the Impact of the ERBB-STAT3 Axis in DFTD(A) Aggressive social interactions in the highly inbred population of Tasmanian devils enabled the rapid spread of DFTD with fatal consequences. The hyperactive ERBB-STAT3 axis induces the expression of downstream metastasis-related genes (i.e., *MMP2*) while suppressing the expression of MHC class I genes (i.e., *B2M*). We hypothesize that highly abundant phosphorylated STAT3 protein traps unphosphorylated STAT1 proteins in heterodimers, thereby preventing the transcriptional regulation of STAT1 downstream target genes such as *B2M*. This may contribute to immune evasion and the known lack of tumor rejection upon horizontal transmission.(B) Interference with the ERBB-STAT3 axis by using either ERBB inhibitors or STAT3 inhibitors results in killing of DFTD tumor cells.

We wish to acknowledge that molecular investigations of non-model organisms can be notoriously hampered by imperfect genome annotations, orthology inferences, and lack of reagents. Several layers of controls were included in this integrative and unbiased systems-biology approach. This was complemented by comparative pathology for which we exploited the high degree of conservation of key oncoproteins driving human cancer, cross-validating a similar driver oncogene scenario in Tasmanian devils.

Our data indicate a positive feedback loop between ERBB receptor tyrosine kinases and STAT3. The underlying mechanism of maintained STAT3 activation, the role of specific STAT3-activating kinases and the apparent lack of negative regulation requires further investigation. Notably, STAT3 S727 phosphorylation is often constitutive in cancer cells associated with hyperactive RAS-RAF signaling, and modulates ATP production in mitochondria through the respiratory chain ([@bib28], [@bib89]). Serine phosphorylation of STAT3 can be catalyzed by many kinases including p38 MAPK, ERK, JNK, CDKs, mTOR, or PKC in response to growth factors such as EGF, PDGF, or Insulin ([@bib12]). Sapitinib efficiently blocked S727 phosphorylation of STAT3 in DFTD cells, while STAT3 inhibition tended to show stronger effects on phosphorylation at residue Y705. Thus, an inhibition of growth factor signaling through sapitinib combined with STAT3 inhibition could be beneficial to synergistically block survival, proliferation, and metabolic functions of STAT3. Not mutually exclusively, the involved processes may include recently detected copy gains of ERBB3 ([@bib31], [@bib83]) leading to enhanced ERBB2-ERBB3 heterodimer activity, the secretion of ligands of the ERBB family, and/or blunted negative regulation by phosphatases or the SOCS pathway.

Histopathologically, DFTD presents as undifferentiated pleomorphic tumor cells with fibrous stroma and occasional infiltrating immune cells ([@bib32], [@bib47], [@bib48]). It is, thus, conceivable that the complex underlying interactions within the tumor microenvironment may contribute to the activation of the ERBB-STAT3 axis. The integrated and unbiased systems-level analysis presented here is expected to provide a critical foundation for further investigations and raises general questions about the tumor biology and transmissibility of such cancers in other species. The implicated canonical cancer signatures apparently do not suffice to give rise to transmissible cancers in humans. Thus, it should be emphasized that the occurrence of transmissible cancers in mammalians is likely to depend on a complex combination of molecular as well as non-molecular context-dependent features, such as aggressive behavior, tissue wounding, and population dynamics ([@bib21]).

Blocking the ERBB-STAT3 axis may present a promising drug target whose interference arrests cancer cells and at the same time leads to increased tumor surveillance through re-expression of MHC class I ([@bib27]). While pharmacological treatments come with inherent logistic limitations for wildlife diseases, this rationalized therapeutic strategy----possibly in combination with a vaccine against DFTD and/or immunotherapeutic interventions----offers a much-needed expansion of the so far limited measures to preserve the Tasmanian devil from extinction.

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**anti-HSC70 monoclonal mouseSanta CruzCat\#sc-7298anti-EGFR monoclonal mouseSanta CruzCat\#sc-373746anti-EGFR monoclonal mouseBD BiosciencesCat\#610016anti-phospho-EGFR (Y1068) monoclonal rabbitCell Signaling TechnologyCat\#3777anti-HER/ErbB2 monoclonal mouseSanta CruzCat\#sc-7301anti-HER2/ErbB2 monoclonal rabbitCell Signaling TechnologyCat\#4290anti-phospho-HER2/ErbB2 (Y1221/1222) monoclonal rabbitCell Signaling TechnologyCat\#2243anti-HER3/ErbB3 monoclonal rabbitCell Signaling TechnologyCat\#12708anti-phospho-HER3/ErbB3 (Y1289) monoclonal rabbitCell Signaling TechnologyCat\#2842anti-Periaxin/PRXSigma AldrichCat\#HPA001868anti-STAT3 monoclonal mouseBD BiosciencesCat\#610189anti-STAT3 monoclonal mouseCell Signaling TechnologyCat\#9139anti-phospho-STAT3 (Y705) polyclonal rabbitCell Signaling TechnologyCat\#9131anti-phospho-STAT3 (Y705) polyclonal rabbitCell Signaling TechnologyCat\#9134anti-pY (4G10)Merck MilliporeCat\#05-321anti-ERK1/2 monoclonal rabbitCell Signaling TechnologyCat\#4695anti-phospho-ERK1/2 (T202/Y204) monoclonal rabbitCell Signaling TechnologyCat\#4370anti-STAT1Cell Signaling TechnologyCat\#9172anti-Kap-1/TRIM28 rabbit polyclonalMerck MilliporeCat\#ABE1859anti-EGFL8 rabbit polyclonalAbcamCat\#ab58650anti-SOCS1Cell Signaling TechnologyCat\#3950anti-B2M[@bib77]N/Aanti-phospho-STAT1 (Y701) (58D6) monoclonal rabbitCell Signaling TechnologyCat\#9167Ki67 (NCL-Ki67p)Leica BiosystemsCat\#KI67-MM1-L-CECleaved Caspase 3 (Asp175)Cell Signaling TechnologyCat\#9661SECL anti rabbit IgG (NA934V)GE HealthcareCat\#NA934anti-mouse (NA931) HRPGE HealthcareCat\#NA931anti-MMP2 polyclonal rabbitAbcamCat\#ab37150**Biological Samples**Devil facial tumor disease 1 (DFT1) biopsy: 08/0038, Mid Tumour T1This paperN/ADevil facial tumor disease 1 (DFT1) biopsy: 08/0195, Mid Tumour T2This paperN/ATasmanian devil spleen biopsy: 08/0195, SpleenThis paperN/ATasmanian devil skin biopsy: 08/0195, SkinThis paperN/ADevil facial tumor disease 1 (DFT1) biopsy: 08/0289, Early Tumour T2This paperN/ADevil facial tumor disease 1 (DFT1) biopsy: 08/0289, Mid Tumour T1This paperN/ATasmanian devil spleen biopsy: 08/0289, SpleenThis paperN/ATasmanian devil skin biopsy: 08/0289, SkinThis paperN/ADevil facial tumor disease 1 (DFT1) biopsy: 08/0590, Mid Tumour T2This paperN/ADevil facial tumor disease 1 (DFT1) biopsy: 08/0590, Late Tumour T1This paperN/ATasmanian devil spleen biopsy: 08/0590, SpleenThis paperN/ATasmanian devil skin biopsy: 08/0590, SkinThis paperN/ADevil facial tumor disease 1 (DFT1) biopsy: 08/1818, Early Tumour T3This paperN/ADevil facial tumor disease 1 (DFT1) biopsy: 08/1818, Mid Tumour T2This paperN/ADevil facial tumor disease 1 (DFT1) biopsy: 08/1818, Late Tumour T1This paperN/ATasmanian devil spleen biopsy: 08/1818, SpleenThis paperN/ATasmanian devil skin biopsy: 08/1818, SkinThis paperN/ATasmanian devil nerve biopsy: ChristineThis paperN/ATasmanian devil nerve biopsy: Curley ShirleyThis paperN/A**Chemicals, Peptides, and Recombinant Proteins**Recombinant devil interferon gamma (rIFNγ)[@bib77]N/AKinase Inhibitor Drug LibraryTargetMol and Cayman ChemicalCat\# L1600 and Cat\# 10505 respectively2K Drug Library[@bib74]N/ASapitinibAdooq BioscienceCat\#A10116LapatinibAdooq BioscienceCat\#A10514PG-S3-009[@bib26]N/ADR-1-55This paperN/A**Deposited Data**Proteomic DataThis paperPRoteomics IDEentification database accession number 1-20180126-165173DNA Methylation DataThis paperGene Expression Omnibus database accession number [GSE108160](ncbi-geo:GSE108160){#intref0010}RNA Seq DataThis paperGene Expression Omnibus database accession number [GSE108107](ncbi-geo:GSE108107){#intref0015}**Experimental Models: Cell Lines**Devil facial tumor disease 1 (DFT1) cell line: 06/2887, Strain 1[@bib18]N/ADevil facial tumor disease 1 (DFT1) cell line: 05/2569, Strain 2[@bib18]N/ADevil facial tumor disease 1 (DFT1) cell line: 06/0368, Strain 3This paperN/ADevil facial tumor disease 1 (DFT1) cell line: 07/0192, Strain 4[@bib35]N/ATasmanian devil fibroblast cell line[@bib57]N/A**Experimental Models: Organisms/Strains**NOD scid gamma (NSG) miceThe Jackson LaboratoryCat\#005557**Oligonucleotides***RPL13A* forward: 5'-CCCCACAAGACCAAGCGAGGC-3'[@bib77]N/A*RPL13A* reverse: 5'-ACAGCCTGGTATTTCCAGCCAACC-3'[@bib77]N/A*EGFR* forward: 5'-GCAGATAGCCAAGGGTATGAGTTACC-3'This paperN/A*EGFR* reverse: 5'-TTTTGCCAGCCCAAAATCTGT-3'This paperN/A*ERBB2* forward: 5'-GGAACCCAAGTGTGCACAGG-3'This paperN/A*ERBB2* reverse: 5'-TGGCATCAGCAGGCAGGTA-3'This paperN/A*ERBB3* forward: 5'-TACATGGTCATGGTTAAGTGCTGG-3'This paperN/A*ERBB3* reverse: 5'-GGTGGATCTCGGGCCATT-3'This paperN/A*MHC-1 (SAHA-UC; KY194695)* forward: 5'-CCGTGGGC\
TACGTGGACGATCAGC-3'[@bib77]N/A*MHC-1 (SAHA-UC; KY194695)* reverse: 5'-GTCGTAGG\
CGAACTGAAG-3'[@bib77]N/A*B2M* forward: 5'-TGTGCATCCTTCCCTACCTGGAGG-3'[@bib77]N/A*B2M* reverse: 5'-CATTGTTGAAAGACAGATCGGACCGC-3'[@bib77]N/A*STAT1* forward: 5'-GGAAAAGCAAGACTGGGACTATGC-3'This paperN/A*STAT1* reverse: 5'-GCGGCTATAGTGCTCATCCAA-3'This paperN/A*STAT3* forward: 5'-GGAAGCTGACCCAGGTAGTGC-3'This paperN/A*STAT3* reverse: 5'-CGGCAGGTCAATGGTATTGC-3'This paperN/A*TRIM28* forward: 5\'-AAGTGCGCACCTCCATCC-3\'This paperN/A*TRIM28* reverse: 5\'-CCCGCTTGTTGAGCTCCTT-3\'This paperN/A*EGF* forward: 5\'-TATGACTGGTACCGGCCCTG-3\'This paperN/A*EGF* reverse: 5\'-TGCCAGCATTAGCTACCACTTGT-3\'This paperN/A*NRG1* forward: 5\'-CAGATACTCGTGCAAGTGCCC-3\'This paperN/A*NRG1* reverse: 5\'-TGCAGATGCCAGTGATGGTC-3\'This paperN/A*EGFL8* forward: 5\'-TCCATACAGCAAGGGAGTTTGC-3\'This paperN/A*EGFL8* reverse: 5\'-ATCCGCTGACCTGCACACA-3\'This paperN/A*HBEGF* forward: 5\'-GGCTGCTCATGTTCAGGTACC-3\'This paperN/A*HBEGF* reverse: 5\'-TTTCCATCAGTGGGCAATAGG-3\'This paperN/A*MMP2* forward: 5′-CAGACAAAGAGTTGGCTGTACAATACC-3′This paperN/A*MMP2* reverse: 5′-CCTTCAGCACAAACAGGTTGC-3′This paperN/A

Contact for Reagent and Resource Sharing {#sec5.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Andreas Bergthaler (<abergthaler@cemm.oeaw.ac.at>).

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Cell Culture and Tissue Biopsies {#sec5.3.1}

DFTD cells were grown from primary cell cultures derived from fine needle aspirates that have been collected from the wild (see [Table S1](#mmc2){ref-type="supplementary-material"}) ([@bib18], [@bib35], [@bib57]). Devil Facial Tumor cell lines T1-4 were grown in RPMI (Gibco 21875-034) supplemented with 10% Fetal bovine serum (PAA A15-101), 1% Pen Strep Glutamine (Gibco 10378-016) and 50 μM 2-Mercaptoethanol (Sigma M-3148). Fibroblasts were grown in Advanced DMEM (Gibco 12491-015) supplemented with 10% Fetal bovine serum (PAA A15-101), 1% Pen Strep Glutamine (Gibco 10378-016). Cells were grown at 35°C in 5% CO~2~ and lifted with either PBS containing 1 mM EDTA or 0.05% Trypsin-EDTA (Gibco 25300-054). CHO supernatants containing recombinant devil interferon gamma (rIFNγ) was used 1:3 diluted ([@bib77]). Control cells received supernatants of wild type CHO cells. The ERBB inhibitors sapitinib (Adooq Bioscience, Cat\# A10116) and lapatinib (Adooq Bioscience, Cat\# A10514) were dissolved in DMSO and used at the indicated concentrations. The STAT3 inhibitors PG-S3-009 and DR-1-55 were dissolved in DMSO and used at the indicated concentrations.

Primary biopsies from Tasmanian devils were obtained from the Department of Primary Industries, Parks, Water and Environment (DPIPWE) (Tasmanian Government, Australia). All animal procedures were performed under a Standard Operating Procedure approved by the Secretary, Wildlife Management Branch, Tasmanian Government Department of Primary Industries, Parks, Water and the Environment (DPIPWE), in agreement with the DPIPWE Animal Ethics Committee. Biopsies were received frozen on dry ice and stored in liquid nitrogen until processed or embedded in paraffin blocks ([Table S1](#mmc2){ref-type="supplementary-material"}).

### Mouse Xenograft Studies {#sec5.3.2}

NOD scid gamma (NSG) mice (JAX \# 005557) were maintained under pathogen-free conditions at the University of Veterinary Medicine, Vienna. Mice were at the age of 8-14 weeks at the time of cell implantation. Mice were kept at 12 hr/12 hr light cycle and received standard food and water *ad libidum*. All animal experiments were approved by the institutional ethics and animal welfare committee of the University of Veterinary Medicine, Vienna and the national authority according to §§ 26ff. of Animal Experiments Act, TVG 2012 BMWFW-68.205/0130-WF/V/3b/2016. The experimental design and number of mice assigned to each treatment arm were based on prior experience with similar models and provided sufficient statistical power to discern significant differences.

For sapitinib treatment mice were matched according to initial tumor size and randomized to treatment with sapitinib or vehicle (ddH~2~O + 1% Tween80). No mice were excluded from the analysis. Mice were implanted subcutaneously in both flanks with 1x10^6^ Devil Facial Tumor cell line 1 ([Table S1](#mmc2){ref-type="supplementary-material"}) in 100 μl PBS, using a 27G needle. Tumor growth was measured every second day using Vernier calipers for the duration of the experiment and tumor volumes were calculated with the following formula: tumor volume = (length × width^2^)/2. Treatment was initiated when the average tumor volume reached approximately 3 mm^3^ and experiments were terminated once tumor volume in control group reached 1 cm^3^. 1 out of 10 transplanted tumors did not grow in each group of mice (n=5). Tumors were resected and used for analysis of tumor weight, immunohistochemistry, real-time PCR and immunoblotting as described.

In the case of DR-1-55 treatment, the mice were randomly divided into two groups and, once the tumor volume reached approximately 3 mm^3^, the mice were treated each second day with DR-1-55 (10 mg/kg) or vehicle (1% DMSO, 5% Tween80, 50% PEG400 in PBS) until tumors in control group reached approximately 1 cm^3^.

Methods Details {#sec5.4}
---------------

### Drug Viability Screen {#sec5.4.1}

We used a combined library of selected 1847 drugs ([@bib74]) and 684 kinase inhibitors (Targetmol catalog no. L1600 and Cayman Chemical item no 10505), which were transferred onto 384-well plates using an acoustic liquid handler (Echo, Labcyte). 5000 cells per well of DFTD cell lines T1-4, and 2500 cells per well of fibroblasts were added on top of the drugs (50 nl in DMSO) with a dispenser (Thermo Fisher Scientific) to a total of 50 μl/well and incubated at 37°C. Cell viability was measured after 72 hr using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega G7573) in a multilabel plate reader (EnVision, PerkinElmer). Initially, all drugs were tested on DFTD cell line \#1 at a single dose (typically 10 μM). 434 drug hits with effects on cell viability were subsequently tested in a 4-dose response in triplicate wells of DFTD cell lines 1 to 4 as well as fibroblasts. Drug candidates were selected based on the difference between the Area Under the Curve (AUC) of each tumor cell line to the control fibroblast higher than 50. The addition of 2 standard deviations of the mean AUC of each strain should also result in a lower value than the subtraction of two standard deviations from the fibroblast AUC ([Equation 1](#fd1){ref-type="disp-formula"}). This yielded 69 candidates that killed at least one DFTD cell line. Out of those, 41 drug candidates killed at least three out of four tumor cell lines but not fibroblasts. These 41 drugs were re-tested as 8-point dose-response in triplicates on the aforementioned five cell lines and cell viability was assessed by CellTiter-Glo as described previously. The STAT3 inhibitors PG-S3-009 ([@bib26]) and DR-1-55 were tested separately as 5-point dose-response curves in triplicates. The percentage of control (POC) was calculated by using linear regression for each plate individually, setting the mean signal of the negative control wells (DMSO) to 100% and the mean signal of the positive control wells to 0%.$$\overline{AUC_{fibroblast}} - 2Sd\left( {AUC_{fibroblast}} \right) > \ \overline{AUC_{tumor\ strains}} - \ 2Sd\left( {AUC_{tumor\ strains}} \right)$$

[Equation 1](#fd1){ref-type="disp-formula"}: Equation identifying significant drugs killing the DFTD tumor strains compared to the fibroblast. AUC stands for area under the curve. Sd stands for standard deviation.

### DNA and RNA Isolation {#sec5.4.2}

For DNA methylation analysis, approximately 20 mg of primary Tasmanian devil tissue was isolated and homogenised using the Tissue Lyser II (Qiagen, Hilden, Germany, 12 x 30 sec, 30 Hz). DNA and RNA were isolated using the AllPrep DNA/RNA Mini Kit (Qiagen, 80204), according to the manufacturer's instructions. For expression analysis from cell lines, total RNA was isolated from approximately 1x10^6^ cells using QIAzol lysis reagent according to the manufacturer's instructions (Qiagen).

### Real-Time PCR {#sec5.4.3}

Isolated RNA was reverse transcribed into cDNA using the First Strand cDNA Synthesis Kit (Fermentas) according to the manufacturer's instructions. Subsequent gene expression was then analysed using SYBR Select Master Mix (Applied Biosystems; 4472908). We designed and used the following gene-specific primers: 5'- CCCCACAAGACCAAGCGAGGC -3' and 5'- ACAGCCTGGTATTTCCAGCCAACC -3' for *RPL13A* ([@bib77]), 5'- GCAGATAGCCAAGGGTATGAGTTACC-3' and 5'- TTTTGCCAGCCCAAAATCTGT-3' for *EGFR*, 5'- GGAACCCAAGTGTGCACAGG-3' and 5'- TGGCATCAGCAGGCAGGTA-3' for *ERBB2*, and 5'- TACATGGTCATGGTTAAGTGCTGG-3' and 5'- GGTGGATCTCGGGCCATT-3' for *ERBB3*, 5'- CCGTGGGCTACGTGGACGATCAGC -3' and 5'- GTCGTAGGCGAACTGAAG -3' for *MHC-1* (*SAHA-*UC; KY194695) ([@bib77]), 5'-TGTGCATCCTTCCCTACCTGGAGG -3' and 5'-CATTGTTGAAAGACAGATCGGACCGC -3' for *B2M* ([@bib77]), 5'- GGAAAAGCAAGACTGGGACTATGC -3' and 5'- GCGGCTATAGTGCTCATCCAA -3' for *STAT1*, 5'- GGAAGCTGACCCAGGTAGTGC -3' and 5'- CGGCAGGTCAATGGTATTGC -3' for *STAT3,* 5\'-AAGTGCGCACCTCCATCC-3' and 5\'-CCCGCTTGTTGAGCTCCTT-3' for *TRIM28*, 5′-TATGACTGGTACCGGCCCTG-3′ and 5′-TGCCAGCATTAGCTACCACTTGT-3′for *EGF*, 5′-CAGATACTCGTGCAAGTGCCC-3′ and 5′-TGCAGATGCCAGTGATGGTC-3′for *NRG1*, 5′-TCCATACAGCAAGGGAGTTTGC-3′ and 5′-ATCCGCTGACCTGCACACA-3′for *EGFL8,* 5′-GGCTGCTCATGTTCAGGTACC-3′ and 5′-TTTCCATCAGTGGGCAATAGG-3′ for *HBEGF,* 5′*-*CAGACAAAGAGTTGGCTGTACAATACC-3′ and 5′-CCTTCAGCACAAACAGGTTGC-3′ for *MMP2.* Designed forward primers span exon-exon junctions where possible.

### Western Blotting {#sec5.4.4}

Approximately 5x10^6^ cells from DFTD strains 1-4 and 2.5x10^6^ Tasmanian devil fibroblasts were pelleted (260 *g*, 5 min, 4°C; [Table S1](#mmc2){ref-type="supplementary-material"}), washed three times in cold PBS, snap frozen in liquid nitrogen and frozen at -80°C until processed. Sample preparation and Western blotting was performed using standard techniques. Nitrocellulose membranes (0.45 μm Amersham Protran 10600002, GE Healthcare, Buckinghamshire, UK) were incubated with the following antibodies in the dilution as indicated (see also [Table S1](#mmc2){ref-type="supplementary-material"}): specific anti-phospho-STAT3 (Y705) polyclonal rabbit (1:1000; 9131; Cell Signaling Technology, Cambridge, UK), anti-STAT3 monoclonal mouse (1:1000; 610189; BD Biosciences, Franklin Lakes, NJ, USA) or (9139; Cell Signaling; 1:1000), anti-phospho-STAT3 (S727) polyclonal rabbit (1:1000; 9134; Cell Signaling Technology, Cambridge, UK), anti-STAT1 (rabbit; 9172; Cell Signaling; 1:1000), anti-phospho-STAT1 (Y701) monoclonal rabbit (1:1000; 9167; Cell Signaling Technology), anti-EGFL8 polyclonal rabbit (1:1000; ab58650; Abcam, Cambridge, UK), anti-phospho-EGFR (Y1068) monoclonal rabbit (1:1000; 3777; Cell Signaling Technology), anti-EGFR monoclonal rabbit (1:1000; sc-373746; Santa Cruz, Dallas, TX, USA), anti-phospho-HER2/ERBB2 (Y1221/1222) monoclonal rabbit (1:1000; 2243; Cell Signaling Technology), anti-ERBB2 monoclonal mouse (1:1000, sc-7301; Santa Cruz Biotechnology), anti-phospho-HER3/ERBB3 (Y1289) monoclonal rabbit (1:1000; 2842; Cell Signaling Technology), anti-HER3/ERBB3 monoclonal rabbit (1:1000; 12708; Cell Signaling Technology), anti-HSC70 monoclonal mouse (1:1000; sc-7298; Santa Cruz), anti-TRIM28 polyclonal rabbit (1:1000; ABE1859; Millipore); anti-ERK1/2 monoclonal rabbit (1:1000; 4695; Cell Signaling Technology, Cambridge, UK), anti-phospho-ERK1/2 (T202/Y204) monoclonal rabbit (1:1000; 4370; Cell Signaling Technology, Cambridge, UK), anti-pY (4G10; Merck Millipore; 1:1000), anti-SOCS (1:1000; 3950; Cell Signaling Technology, Cambridge, UK), anti-B2M (1:1000; ([@bib77])), ECL anti-rabbit IgG (NA934V) or anti-mouse (NA931) HRP (1:10000; GE Healthcare, Buckinghamshire, UK).

### Immunoprecipitation {#sec5.4.5}

Cells were lysed in HE buffer (10 mM HEPES (pH 7.35), 1 mM EDTA) supplemented with protease inhibitors using a dounce tissue grinder. Human HT-29 cells (ATCC HTB-38) served as control. For immunoprecipitation, 1 mg protein lysate was incubated with 2 μg of anti-STAT3 (9139; Cell Signaling) or anti-STAT1 (9172; Cell Signaling) at 4°C overnight and immunoprecipitated with 25 μl Dynabeads Protein G (10004D; Thermo Fisher Scientific, Waltham, MA, USA) for 2 hr at 4°C. Beads were washed 3x with HE buffer and samples were eluated in 40 μl Laemmli buffer at 95°C for 10 min.

### Histology {#sec5.4.6}

DFTD tissues of diseased animals (328T1 and 463T1) were fixed in 10% neutral buffered formalin and paraffin-embedded. 2 μm FFPE consecutive tumor sections were stained with Hematoxylin (Merck, Darmstadt, Germany) and Eosin G (Carl Roth). For immunohistochemical stainings, heat-mediated antigen retrieval was performed in citrate buffer at pH 6.0 (S1699; Dako, Agilent, Santa Clara, CA, USA), EDTA at pH 8.0 or TE at pH 9.0. Sections were stained with antibodies specific to STAT3 (1:200; pH 6; 9139; Cell Signaling Technology), phospho-STAT3 (S727) monoclonal rabbit (1:80; pH 9; 9134; Cell Signaling Technology); EGFR monoclonal mouse (1:300; 610016; pH 9; BD Biosciences), HER2/ERBB2 monoclonal rabbit (1:200, 4290; Cell Signaling Technology), HER3/ERBB3 monoclonal rabbit (1:200, 12708; Cell Signaling Technology), Periaxin/PRX (1:200, HPA001868, Sigma Aldrich), MMP2 (1:200; ab37150, Abcam), Ki67 (1:1000; NCL-Ki67p; Novocastra, Leica Biosystems;) or Cleaved Caspase 3 (Asp175) (1:200, 9661S, Cell Signaling Technology) using standard protocols (see also [Table S1](#mmc2){ref-type="supplementary-material"}). Images were photographed using an Olympus BX 53 microscope, and were quantified using HistoQuest TM software (TissueGnostics GesmbH, Vienna, Austria).

### Immunofluorescence {#sec5.4.7}

Cells were grown on sterile glass coverslips, rinsed with PBS, fixed in 4% paraformaldehyde for 10 min and permeabilized using 0.5% Triton X-100 in PBS for 8 min. Cells were blocked in 3% BSA+0.1% Triton in PBS for 1 hr, incubated with primary antibodies (anti-STAT1 1:500, 9172 Cell Signaling Technology; anti-STAT3 1:1500, 9139 Cell Signaling Technology) for 1 hr or at 4°C overnight, washed and probed with the secondary antibodies conjugated to Alexa Fluor 488 and Alexa Fluor 568 (Molecular Probes) for 1 hr. Cells were stained with DAPI and mounted in VECTASHIELD Antifade Mounting Medium with DAPI (Vector Laboratories). The images were acquired with a Zeiss LSM 880 Confocal Laser Scanning Microscope.

### Mass-Spectrometry Based Proteomics {#sec5.4.8}

#### Sample Preparation for MS {#sec5.4.8.1}

Approximately 1x10^7^ cells from DFT1 tumor cell line T1 were pelleted (260*g*, 5 min, 4°C), washed three times in PBS and frozen at -80°C until processed. Primary biopsies were thawed and placed in a petri dish. Using a scalpel blade, 5×5 to 5×8 mm pieces of tissue were excised from the solid mass and placed in a 2 ml Eppendorf tube. Depending on the size of the piece of tissue, 500-1000 μl of lysis buffer (50 mM HEPES, pH 8.0, 2% SDS, 1 mM PMSF, and protease inhibitor cocktail (Sigma-Aldrich)) was added to the tumour and skin samples. Samples were homogenised using the Tissue Lyser II (Qiagen, Hilden, Germany) for 4×2 min, 30 Hz. For some samples, it was necessary to repeat the homogenization procedure. Spleen samples were pre-cleared of blood before tissue lysis. Tissue pieces were placed in a 2 ml Eppendorf tube containing 1 ml red blood cell (RBC)-lysis buffer (eBioscience, San Diego, USA). Spleen tissue was homogenised using the Tissue Lyser II (Qiagen, Hilden, Germany) for 3×30s, centrifuged at 20000 *g* for 10 min and supernatant containing the lysed red blood cells removed. Lysis was performed at room temperature (RT) for 20 min. Lysed samples were heated at 99°C for 5 min and then cooled to RT. The cell lysate was sonicated using a Covaris S2 high performance ultrasonicator (Covaris Inc., Brighton, UK). The lysate was centrifuged at 20000 *g* for 15 min at 20°C, and the protein extract was collected from the supernatant. Total protein content of the whole tissue lysates was determined using the BCA protein assay kit (Pierce Biotechnology, Rockford, IL) following the recommendations of the manufacturer. The assay was performed in a 96-well plate using 10 μl of each lysate and standard protein. The samples were measured in triplicates. Bovine serum albumin (BSA) (Pierce Biotechnology, Rockford, IL) was used as the standard protein.

#### Filter-Aided Sample Preparation (FASP) {#sec5.4.8.2}

100 μg total protein per tissue was used for FASP digestion. Dithiothreitol (DTT; SIGMA-Aldrich Chemie, Vienna, Austria) was added to sample to a final concentration of approx. 83 mM. After incubation of the samples at 99°C for 5 min, FASP digestion was performed using a 30 kDa molecular weight cut-off filter (Microcon-30, Ultracel YM-30, Merck-Millipore Co., Cork, IRL) ([@bib92]). Briefly, 200 μL 8 M urea in 100 mM Tris-HCl (pH 8.5) (UA) was added to the samples. If the volume exceeded 50 μl, then 400 μl UA was added. After equilibration of the filter units with 200 μl UA and centrifugation at 14000×*g* for 15 min, the lysed samples were applied in steps of 250 μl to the filter unit and centrifuged at 14000 *g* for 15 min at 20°C to remove SDS. Any remaining SDS was exchanged by urea in a second washing step with 200 μl UA. The proteins were alkylated with 100 μl 50 mM iodoacetamide (Sigma-Aldrich Chemie, Vienna, Austria) for 30 min at RT. Afterwards, three washing steps with 100 μL UA solution were performed, followed by three washing steps with 100 μL 50 mM TEAB buffer (Sigma-Aldrich, Vienna, Austria). Proteins were digested with Trypsin overnight at 37°C. Peptides were recovered using 40 μl 50 mM TEAB buffer followed by 50 μl of 0.5 M NaCl (Sigma-Aldrich, Vienna, Austria).

Two-dimensional liquid chromatography was performed by reverse-phase chromatography at high and low pH. FASP digests were purified by solid-phase extraction (SPE) (MacroSpin Columns, 30-300 μg capacity, Nest Group Inc. Southboro, MA, USA) and reconstituted in 23 μl 5% acetonitrile, 10 mM ammonium formate. Peptides were separated on a Gemini-NX C18 (150 × 2 mm, 3 μm, 110 Å, Phenomenex, Torrance, US) using a 30 min gradient from 5 to 90% acetonitrile containing 10 mM ammonium formate buffer, pH 10, at a flow rate of 100 μl/min, using an Agilent 1200 HPLC system (Agilent Biotechnologies, Palo Alto, CA). Details of the methodology are as described previously ([@bib7]). Ten time-based fractions were collected. Samples were acidified by the addition of 5μl 5% formic acid. Solvent was removed in a vacuum concentrator, and samples were reconstituted in 5% formic acid. Liquid chromatography mass spectrometry was performed on a hybrid linear trap quadrupole (LTQ) Orbitrap Velos mass spectrometer (ThermoFisher Scientific, Waltham, MA) using the *Xcalibur version 2.1.0* coupled to an Agilent 1200 HPLC nanoflow system (dual pump system with one trap-column and one analytical column) via a nanoelectrospray ion source using liquid junction (Proxeon, Odense, Denmark). Solvents for HPLC separation of peptides were as follows: solvent A consisted of 0.4% formic acid (FA) in water, and solvent B consisted of 0.4% FA in 70% methanol and 20% 2-propanol. From a thermostatted microautosampler, 8 μl of the tryptic peptide mixture were automatically loaded onto a trap column (Zorbax 300SB-C18 5 μm, 5×0.3 mm, Agilent Biotechnologies) with a binary pump at a flow rate of 45 μl/min. 0.1% trifluoroacetic acid (TFA) was used for loading and washing the precolumn. After washing, the peptides were eluted by back-flushing onto a 16 cm fused silica analytical column with an inner diameter of 50 μm packed with C18 reversed phase material (ReproSil-Pur120 C18-AQ, 3 μm, Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). The peptides were eluted from the analytical column with a 27 min gradient ranging from 3% to 30% solvent B, followed by a 25 min gradient from 30% to 70% solvent B, and finally a 7 min gradient from 70% to 100% solvent B at a constant flow rate of 100 nl/min ([@bib7]). The analyses were performed in a data-dependent acquisition mode, and dynamic exclusion for selected ions was 60s. A top 15 collision-induced dissociation (CID) method was used, and a single lock mass at *m/z* 445.120024 (Si(CH~3~)~2~O)~6~) was employed ([@bib64]). Maximal ion accumulation time allowed in CID mode was 50 ms for MSn in the LTQ and 500 ms in the C-trap. Automatic gain control (AGC) was used to prevent overfilling of the ion traps and was set to 5000 in MS^2^ mode for the LTQ and 10^6^ ions for a full MS^1^ FTMS scan. Intact peptides were detected in the Orbitrap Velos at a resolution of 60000 resolution (at *m/z* 400). The threshold for switching from MS^1^ to MS^2^ was 2000 counts.

### DNA Methylation Analysis {#sec5.4.9}

DNA methylation profiling by RRBS was performed as described previously using 100 ng of genomic DNA isolated from RNA-later preserved tissue samples through the Allprep DNA/RNA Mini kit (QIAGEN) ([@bib41]). Methylated and unmethylated spike-in controls were added in a concentration of 0.1% to assess bisulfite conversion efficiency independent of CpG context. DNA was digested using the restriction enzymes MspI and TaqI in combination (as opposed to only MspI in the original protocol) in order to increase genome-wide coverage. Restriction enzyme digestion was followed by fragment end repair, A-tailing, and adapter ligation. The amount of effective library was determined by qPCR, and samples were multiplexed in pools of 13 with similar qPCR *C*~*t*~ values. The pools were then subjected to bisulfite conversion followed by library enrichment by PCR. Enrichment cycles were determined using qPCR and ranged from 9 to 13 (median: 11). After confirming adequate fragment size distributions on Bioanalyzer High Sensitivity DNA chips (Agilent), libraries were sequenced on Illumina HiSeq 3000/4000 machines in a 50 bp single-read setup.

### Transcriptome Expression Analysis and Variant Calling {#sec5.4.10}

The amount of total RNA was quantified using Qubit 2.0 Fluorometric Quantitation system (Life Technologies) and the RNA integrity number (RIN) was determined using Experion Automated Electrophoresis System (Bio-Rad). RNA-seq libraries were prepared with TruSeq Stranded mRNA LT sample preparation kit (Illumina) using Sciclone and Zephyr liquid handling robotics (PerkinElmer). Library amount was quantified using Qubit 2.0 Fluorometric Quantitation system (Life Technologies) and the size distribution was assessed using Experion Automated Electrophoresis System (Bio-Rad). For sequencing 6 libraries were pooled, diluted and sequenced on Illumina HiSeq 3000/4000 using 75 bp paired-end chemistry. Base calls provided by the Illumina Realtime Analysis software were converted into BAM format using Illumina2bam and demultiplexed using BamIndexDecoder (<https://github.com/wtsi-npg/illumina2bam>).

### Measurement of Biochemistry Parameters {#sec5.4.11}

Serum was prepared by centrifugation of the whole blood for 20 min at 7000 rpm. Serum concentration of alanine aminotransferase, aspartate aminotransferase and blood urea nitrogen was measured using a chemistry analyzer (IDEXX VetTest 8008, IDEXX GmbH, Ludwigsburg, Germany).

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

### Immunohistochemistry and Immunofluorescence Quantification {#sec5.5.1}

Immunohistochemical images were taken with Olympus BX 53 microscope and the quantification was performed using HistoQuest TM software (TissueGnostics GesmbH, Vienna Austria). Quantification of immunofluorescence was carried out using a co-localization pipeline of CellProfiler (version 3.1.5). Briefly, illumination was corrected using the \"Regular\" function and \"Fit polynomial\" as smoothing method. Subsequently, images were aligned with the \"Mutual information\" option and objects were identified with the following settings: size (pixels) 3-15, Threshold strategy: global, Threshold method: Otsu, with three classes thresholding, pixels in the middle intensity class were assigned as background and objects touching the image boundary were discarded. Objects were classified as co-localized if they touched, overlapped or enclosed each other and as not co-localized when none of the above applied. Percentages were calculated on a per image basis and for each condition 10 images were used. Data shown is representative of three similar experiments. Displayed is the percentage of STAT1 objects that were colocalized with a STAT3 object.

### Mass-Spectrometry Based Proteomics - Quantification {#sec5.5.2}

The data were analyzed using Proteome Discoverer version 2.2 against the Uniprot Tasmanian Devil fasta database version 2016.11 including isoforms obtained by VARSPLIC ([@bib39]) and appended with known contaminants (91064 sequences total). The precursor masses were first recalibrated using the recalibration node (parameters: precursor mass tolerance: 20 ppm, fragment mass tolerance 0.5 Da, Carbamidomethylation of cysteine as static modification). The recalibrated data were then searched using Sequest HT ([@bib20]) and Mascot (v2.3.02, MatrixScience, London, U.K.) ([@bib68]) search engines with precursor mass tolerance being 4 ppm, fragment ion tolerance was 0.3 Da, methionine oxidation used as dynamic modification, and carbamidomethylation of cysteine as static modification in both search engines. Moreover protein N-terminal acetylation was considered as dynamic modification in Sequest HT. Minimum length of peptides was set to 6 and maximum number of missed cleavages was set to two in Sequest HT and to one in Mascot. Percolator ([@bib37]) was used to filter peptide-spectra matches (PSMs) at 1% false discovery rate (FDR) and QVALITY ([@bib38]) to filter identified peptides at 1% FDR. Identified proteins were also filtered at 1% FDR by considering sum of negative logarithm of posterior error probabilities of connected PSMs. Matches against reversed fasta database were used to estimate FDR at PSM, peptide, and protein level. Abundance of proteins was quantified using the Minora feature detection node and integrating area under the MS1 chromatogram.

Principal component analysis was performed on 3894 out of 6672 proteins quantified in all 19 samples. We further focused on 4981/6672 proteins quantified in at least 80% of the samples. The protein abundance data was normalized by variance stabilizing transformation ([@bib33]). Missing values are imputed on normalized abundance values with the k Nearest Neighbors (kNN) algorithm implemented in the R Bioconductor package impute ([@bib30]).

For each protein with a missing abundance in any of the samples, the kNN algorithm identifies the set of 10 most similar proteins based on non-missing abundance values. Missing abundance is then imputed as an average abundance in that set. An average of the signal is then performed on the k closest neighbours. Differential analysis, tumor versus the healthy, was performed between biopsies (excluding the tumor cell line) using the limma Bioconductor package ([@bib70]). Proteins were considered as differentially modulated if their adjusted p value was \<= 0.05 and their absolute log2 Fold Change was \>=1 between tumor and healthy biopsies. Hierarchical clustering of the 987 differentially modulated proteins was performed with Pearson's distance measure and the average clustering method.

### DNA Methylation Analysis and Quantification {#sec5.5.3}

The DNA methylation (RRBS) data were analyzed using the RefFreeDMA pipeline as described previously to avoid potential biases in read mapping and methylation calling related to the scaffold assembly status of the published Tasmanian Devil reference genome sarHar1 ([@bib41]). In brief, a custom *ad-hoc* reference genome was deduced directly from the RRBS sequencing reads and used for read mapping and methylation calling. Based on the thus produced DNA methylation profiles, differential DNA methylation analysis was performed as part of the RefFreeDMA pipeline and as originally described in ([@bib4]). Gene annotations were transferred by mapping the deduced genome fragments to the published scaffold-level Tasmanian Devil genome sarHar1, downloaded from the UCSC genome browser. A gene annotation file was produced by joining the UCSC transcript annotation file with the Ensembl v86 transcript annotation file of sarHar1 based on the common Ensembl transcript identifiers. Gene promoters were defined as the region between 5000 bases downstream and 2500 bases upstream of the transcription start site. 487540 (11.37%) of the individual CpGs are situated in promoters of annotated genes. For promoter methylation analysis we focused on a total of 69754 CpGs that are also covered in at least 80% of the samples. The significance of differential methylation throughout promoters or deduced genome fragments was assessed by combining the p values for single CpGs within the respective promoter regions or deduced genome fragments using an extension of the Fisher's method as described previously ([@bib4], [@bib41]).

### Western Blot Quantification {#sec5.5.4}

Immunoblots were quantified using ImageJ (2.0.0) software. Three independent immunoblots were used for each quantification. Phospho-STAT3 levels were normalized to STAT3 and to loading control HSC70.

### Transcriptome Expression Analysis and Variant Calling {#sec5.5.5}

Paired-end reads were trimmed for adaptor sequences and filtered with the trimmomatic tool ([@bib8]). Trimmed reads were aligned on the version 7.0 of the Tasmanian Devil with the STAR aligner ([@bib19]). Counting of reads on annotated transcripts (Sarcophilus_harrisii.DEVIL7.0.90.gtf from Ensembl) was performed with featureCounts ([@bib46]). The DESeq2 Biconductor library has been used for counts normalization and differential analysis between the transcriptomes of the four DFTD and fibroblast cell lines ([@bib49]). Differentially expressed genes were identified based on the following cutoffs: an average minimum expression value between conditions of 50 reads, an absolute log fold change of 1, and an adjusted p value of maximum 0.05. The pipeline for variant calling is based on the GATK version 3.7, following the best-practices ([@bib87]). Called variants were annotated with SNPEff v4.2 ([@bib13]). Variants are filtered on strand bias (\<30), quality (QD \> 2), coverage (DP \>= 10) and allele frequency (AF = 0.5).

### Network Analysis {#sec5.5.6}

We performed Transcription Factor and Pathway Maps enrichment on the differentially modulated entities (proteins, genes) with the MetaCore™ (Thomson Reuters, version 6.32 build 69020; cut-off for p value of enrichment 0.05). The results are reported based on the z-score of enrichment for the transcription factors and as -log10 of the False Discovery Rate for the Pathway Maps. The 987 differentially modulated proteins were integrated together with the 166 genes with differentially modulated promoters and the candidates ERBB2 and ERBB3 from the drug-screen at the level of MetaCore interactions (Build Network functionality). Only high-confidence direct interactions between pairs of genes are considered: protein binding, transcription factor regulation, other functional interaction. 632 of the previous candidates form a direct network connection.

### Motif Enrichment Analysis {#sec5.5.7}

We filtered individual CpG regions with less than 8 or more than 200 reads. On the remaining CpGs, we only kept those with less than 20% missing values across the 19 samples. Modulated individual CpGs between healthy and tumor samples were selected based on an adjusted p value smaller than 0.05, and a log fold-change greater than 1 for the UP dataset (4299 CpGs), and smaller than -1 for the DOWN dataset (1727 CpGs). Fasta sequences of these fragments were extracted. We performed motif enrichment analysis with the AME tool from the MEME package ([@bib52]). We used the motif JASPAR CORE 2014 Vertebrate database ([@bib50]). The motif enrichment for each fasta file accounts for background sequence composition by using the other sequence file as control.

### Integrating DFTD Quantifications across Techniques {#sec5.5.8}

The DFTD tumor cell line T1 was the only sample quantified with all three techniques: RNA-seq, proteomics and methylation. We kept only the annotated (no SNO) genes from the RNA-seq data and computed the expression as the number of counts divided by the length of the gene as returned by featureCounts ([@bib46]). The genes were ranked according to expression from the most to the least expressed. The top 15% most abundant proteins (817) were selected. We performed a Gene Set Enrichment Analysis (GSEA) ([@bib56], [@bib82]). Pre-ranked between the top DFTD 15% most abundant proteins and the ranked gene expression data using default parameters. For the annotated gene promoters with CpG fragments, we computed the average methylation level in the promoter regions defined as -5 kb to 2.5 kb around the TSS. Similarly, we ranked the genes according to their promoter methylation level. We selected the top 15% least methylated gene promoters (936) and performed GSEA Pre-ranked on the ranked RNA-seq expression. Alternatively, we ranked the annotated genes detected in the DFTD cell line by both RNA-seq and methylation data with a random method for ties. We compared the ranks of methylation and transcriptomics using the hexbin plot in R (hexbin R package (version 1.27.2). A Spearman correlation is performed between the ranks of the two datasets.

To study potential effects on chemotaxis and cytoskeleton remodeling, we performed MetaCore Pathway Enrichments on all proteins that were modulated, be it UP or DOWN (abs(logFC) \>= 1, adj.p.val \<= 0.05; [Table S5](#mmc6){ref-type="supplementary-material"}). Subsequently, we extracted proteins that were differentially modulated and led to the enrichments in the following pathways linked to chemotaxis and cytoskeleton remodeling: Cytoskeleton remodeling_Integrin outside-in signaling (4), Chemotaxis_SDF-1/CXCR4-induced chemotaxis of immune cells (5), Cytoskeleton remodeling,\_Regulation of actin cytoskeleton organization by the kinase effectors of Rho GTPases (9) and Cell adhesion_Role of tetraspanins in the integrin-mediated cell adhesion (13). The respective proteins are reported in [Table S5](#mmc6){ref-type="supplementary-material"} the chemotaxisGenes.xlsx file together with their respective modulation in the Proteomics and RNAseq datasets. Next, we generated a heatmap based on the protein abundance values of these proteins across the biopsies, cell line, nerve, skin and spleen (clustering distance : pearson, clustering method: average). On the right genes that were found as being bound by STAT3 across any of the ENCODE Chip-seq datasets ([@bib72]) were color-coded. In addition, we color-coded whether the genes were found and/or modulated in the RNA-seq data (DFTD tumor cell lines T1-T4 vs. fibroblasts).

### Characterization of the STAT3 Inhibitor DR-1-55 {#sec5.5.9}

To characterize drug-target binding, we performed a ^19^F NMR protein-ligand experiment as done previously ([@bib1], [@bib26], [@bib91]). Incubation of purified recombinant STAT3 with DR-1-55 results in line broadening of the ^19^F peaks from the compound, indicating a longer correlation time for the drug, which is a consequence of protein-drug binding. Concomitantly, a release of fluoride ions is observed, the by-product of a covalent reaction of the protein and a pentafluorobenzene containing molecule. In addition, we performed a thermal shift assay and observed a dose-dependent decrease in the denaturation temperature of recombinant STAT3, indicative of covalent protein-ligand binding interaction ([@bib17]).

Data and Software Availability {#sec5.6}
------------------------------

The data reported in this paper are tabulated in the [Supplemental Information](#mmc1){ref-type="supplementary-material"} and archived at the following databases: proteomic data in the PRoteomics IDEentification (PRIDE) database with accession number (1-20180126-165173), DNA methylation data in the Gene Expression Omnibus (GEO) database with accession number ([GSE108160](ncbi-geo:GSE108160){#intref0030}) and RNA-seq data in the GEO database with accession number ([GSE108107](ncbi-geo:GSE108107){#intref0035}).

Supplemental Information {#app2}
========================

Document S1. Figures S1--S6Table S1. Description of Cell Lines, Sample Biopsies, and Antibodies Used in This Study, Related to Figure 1Table S2. List of Drug Hits, Related to Figure 1Table S3. Differential Expression Analysis of RNA Sequencing Data, Related to Figure 1Table S4. Variant Calling Analysis, Related to Figure 1Table S5. Mass Spectrometry-Based Proteomics, Related to Figure 2Table S6. Differential Analysis of DNA Methylation, Related to Figure 2Document S2. Article plus Supplemental Information

We thank Thomas Penz and the Biomedical Sequencing Facility at CeMM and Fiorella Schischlik with technical support for sequencing and analysis, Kathrin Runggatscher for technical support with the drug screen, Young Mi Kwon and Jinhong Wang with logistical support, and Michael Moschinger and Theresa Pinter for discussions. We thank Safia Zahma for histopathology and immunohistochemistry processing, and Thomas Grunt and Herwig Moll for advice on reagents for ERBB family members. The authors would like to thank Ruedi Aebersold, Lukas Flatz, Stephen P. Goff, Nancy Hynes, Christopher Schliehe, Giulio Superti-Furga, and Rolf M. Zinkernagel for valuable feedback and discussions.

This work was supported by funding from the Austrian Academy of Sciences (to A.B.), the Austrian Science Fund (FWF) DK W1212 (to B.A. and A.B.), and the European Research Council (ERC) under the European Union\'s Seventh Framework Program and Horizon 2020 research and innovation program (grant agreement no. 677006, "CMIL" to A.B.). B.W. and R.M. received funding via FWF SFB F4707-B20 and SFB-F06105. A.O. is supported by the Austrian Research Promotion Agency (FFG, no. 854452).

Author Contributions {#sec6}
====================

L.K., B.W., A.O., B.A., B.V., K.P., A.L., A.R., J.K., and E.D.d.A. conducted the experiments and analyzed the data. A.P., P.M., K.K., H.B., C.B., S.K., K.L.B., R.M., and A.B. analyzed the data. D.A.R., J.P., G.T., S.A., P.T.G., H.V.S., G.M.W., and E.P.M. provided the material. L.K., A.P., B.V., R.M., and A.B. wrote the manuscript. A.B. conceived and supervised the study.

Declaration of Interests {#sec7}
========================

The authors declare no competing interests.

Supplemental Information includes six figures, six tables, and one video and can be found with this article online at [https://doi.org/10.1016/j.ccell.2018.11.018](10.1016/j.ccell.2018.11.018){#intref0040}.

A video abstract is available at [https://doi.org/10.1016/j.ccell.2018.11.018\#mmc8](10.1016/j.ccell.2018.11.018#mmc8){#intref0045}.

[^1]: These authors contributed equally

[^2]: Senior author

[^3]: Lead Contact
